DUBLIN–(BUSINESS WIRE)–The “Rituximab – Biosimilars Insight, 2020” report has been added to ResearchAndMarkets.com’s offering.
This Rituximab- Biosimilar Insight, 2020 report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Rituximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Rituximab Biosimilars: Drugs Chapters
This segment of the Rituximab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rituximab Biosimilars: Marketed Drugs
Blitzima: Celltrion
Blitzima is a medicine used in adults to treat the following blood cancers and inflammatory conditions: follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer); chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells); granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) and microscopic polyangiitis (MPA), which are inflammatory conditions of the blood vessels. Depending on the condition it is used to treat, Blitzima may be given with chemotherapy (other cancer medicines) or medicines used for inflammatory disorders (corticosteroids). Blitzima contains the active substance rituximab.
Rixathon: Sandoz
Rixathon is approved for non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. (Read more…) Depending on the condition it is used to treat, Rixathon may be given on its own, or with chemotherapy (cancer medicines) or medicines used for inflammatory disorders (methotrexate or a corticosteroid).
Rituximab Biosimilars: Emerging Drugs
IBI301: Innovent Biologics
IBI301 is a potential biosimilar of rituximab, a recombinant human-mouse chimeric anti-CD20 monoclonal antibody for injection, and is being co-developed by Innovent and Eli Lilly and Company. Rituximab binds to the CD20 antigen on the surface of B lymphocytes and mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Normal and malignant B cells are targeted for destruction by the antibody, thereby achieving anti-tumor and immunosuppressive therapeutic effects.
ABP 798: Allergan/Amgen
ABP 798 has been developed as a biosimilar candidate to Rituxan. Rituxan is an anti-CD20 monoclonal antibody that has been approved in many regions for the treatment of, among other things, adult patients alone or in combination with chemotherapy for non-Hodgkin’s lymphoma, in combination with fludarabine and cyclophosphamide for chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis with glucocorticoids. The active ingredient of ABP 798 is a monoclonal antibody that has the same amino acid sequence as Rituxan.
Rituximab: Therapeutic Assessment
This segment of the report provides insights about the different Rituximab biosimilars segregated based on following parameters that define the scope of the report, such as:
Major Players in Rituximab
There are approx. 35+ key companies which are developing the therapies for Rituximab.
Phases
This report covers around 35+ products under different phases of clinical development like
- Marketed stage products
- Late stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Rituximab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Rituximab: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Rituximab biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rituximab biosimilar drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rituximab R&D. The therapies under development are focused on novel approaches to treat/improve Rituximab.
- In January 2019, Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE (rituximab), a potential biosimilar to MabThera (rituximab).
- In December 2019, Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.
- In November 2019, Teva Pharmaceuticals and Celltrion Healthcare announced that TRUXIMA (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan1 (rituximab) now available in the United States with a full oncology label. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL):
Rituximab Biosimilars Report Insights
- Rituximab Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
Rituximab Biosimilar Report Assessment
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rituximab Biosimilars?
- How many Rituximab biosimilars are developed by each company?
- How many emerging biosimilars are in mid-stage, and late-stage?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rituximab biosimilars therapeutics?
- What are the clinical studies going on for Rituximab biosimilars and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Innovent Biologics
- IQVIA (formely Quintiles Transnational Corp)
- Gedeon Richter
- BioIntegrator
- Allergan
- Amgen
- Biocad
- Celltrion
- BioXpress Therapeutics
- Dr. Reddy’s Laboratories Limited
- Sandoz
- Shanghai Henlius Biotech
- iBio
- Inbiopro Solutions
- Merck & Co.
- Gedeon Richter
- Zydus Cadila
- Curaxys
- Outlook Therapeutics
- Apotex
- mAbxience
- Pfizer
- Nichi-Iko Pharmaceutical/Aprogen
- Sunshine Guojian Pharmaceutical
- Lonza
- Teva Pharmaceutical Industries
- Reliance Life Sciences
- PROBIOMED
- LG Chem
- GC Pharma
- Hetero Group
- HisunPharmaceuticals
- BioXpress Therapeutics
- International Biotech Center Generium
Key Products
- IBI-301
- RGB 03
- RITUMAX
- ABP 798
- AcellBia/Usmal
- Blitzima/Truxima
- BX 2336
- DRL_RI
- GP2013
- HLX01
- iBio Rituximab
- IBPB 001RX
- MK-8808
- Ritemvia/Blitzima
- Riximyo
- RTXM83
- Ruxience
- AP 052
- Retuxira
- TL-011
- RituxiRel
- Kikuzubam
- LBRx
- DRL-rituximab
- MG1106
- GB-241
- Rilast
- HS 006
- BX 2336
- GNR-006
For more information about this report visit https://www.researchandmarkets.com/r/ii99q1
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900